A	a	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
dose-comparison	dose-comparison	O	O	O	O
trial	trial	O	O	O	O
of	of	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
psychosis	psychosis	O	DISEASE	OTHERS	I
and	and	O	O	O	O
disruptive	disruptive	O	O	OTHERS	I
behaviors	behaviors	O	O	OTHERS	I
in	in	O	O	O	O
Alzheimer	alzheimer	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
goal	goal	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
compare	compare	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
two	two	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
placebo	placebo	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
psychosis	psychosis	O	DISEASE	OTHERS	I
and	and	O	O	O	O
disruptive	disruptive	O	O	OTHERS	I
behaviors	behaviors	O	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
Alzheimer	alzheimer	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

METHOD	method	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
a	a	O	O	O	O
6-week	6-week	O	O	O	O
random-assignment	random-assignment	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
,	,	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
trial	trial	O	O	O	O
(	(	O	O	O	O
phase	phase	O	O	O	O
A	a	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
2	2	O	O	O	O
-	-	O	O	O	O
3	3	O	O	O	O
mg/day	mg/day	O	O	O	O
(	(	O	O	O	O
standard	standard	O	O	O	O
dose	dose	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
0.50	0.50	O	O	O	O
-	-	O	O	O	O
0.75	0.75	O	O	O	O
mg/day	mg/day	O	O	O	O
(	(	O	O	O	O
low	low	O	O	O	O
dose	dose	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
were	were	O	O	O	O
compared	compared	O	O	O	O
in	in	O	O	O	O
71	71	O	O	O	O
outpatients	outpatients	O	O	O	O
with	with	O	O	O	O
Alzheimer	alzheimer	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

For	for	O	O	O	O
the	the	O	O	O	O
subsequent	subsequent	O	O	O	O
6-week	6-week	O	O	O	O
double-blind	double-blind	O	O	O	O
crossover	crossover	O	O	O	O
phase	phase	O	O	O	O
(	(	O	O	O	O
phase	phase	O	O	O	O
B	b	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
patients	patients	O	O	O	O
taking	taking	O	O	O	O
standard-	standard-	O	O	O	O
or	or	O	O	O	O
low-dose	low-dose	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
switched	switched	O	O	O	O
to	to	O	O	O	O
placebo	placebo	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
patients	patients	O	O	O	O
taking	taking	O	O	O	O
placebo	placebo	O	O	O	O
were	were	O	O	O	O
randomly	randomly	O	O	O	O
assigned	assigned	O	O	O	O
to	to	O	O	O	O
standard-	standard-	O	O	O	O
or	or	O	O	O	O
low-dose	low-dose	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
For	for	O	O	O	O
the	the	O	O	O	O
60	60	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
completed	completed	O	O	O	O
phase	phase	O	O	O	O
A	a	O	O	O	O
,	,	O	O	O	O
standard-dose	standard-dose	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
efficacious	efficacious	O	O	O	O
and	and	O	O	O	O
superior	superior	O	O	O	O
to	to	O	O	O	O
both	both	O	O	O	O
low-dose	low-dose	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
placebo	placebo	O	O	O	O
for	for	O	O	O	O
scores	scores	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
Brief	brief	O	O	O	O
Psychiatric	psychiatric	O	DISEASE	OTHERS	I
Rating	rating	O	O	O	O
Scale	scale	O	O	O	O
psychosis	psychosis	O	DISEASE	OTHERS	I
factor	factor	O	O	O	O
and	and	O	O	O	O
on	on	O	O	O	O
psychomotor	psychomotor	O	DISEASE	OTHERS	I
agitation	agitation	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Response	response	O	O	O	O
rates	rates	O	O	O	O
according	according	O	O	O	O
to	to	O	O	O	O
three	three	O	O	O	O
sets	sets	O	O	O	O
of	of	O	O	O	O
criteria	criteria	O	O	O	O
were	were	O	O	O	O
greater	greater	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
standard	standard	O	O	O	O
dose	dose	O	O	O	O
(	(	O	O	O	O
55%-60	55%-60	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
than	than	O	O	O	O
the	the	O	O	O	O
low	low	O	O	O	O
dose	dose	O	O	O	O
(	(	O	O	O	O
25%-35	25%-35	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
placebo	placebo	O	O	O	O
(	(	O	O	O	O
25%-30	25%-30	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
advantage	advantage	O	O	O	O
of	of	O	O	O	O
standard	standard	O	O	O	O
dose	dose	O	O	O	O
over	over	O	O	O	O
low	low	O	O	O	O
dose	dose	O	O	O	O
was	was	O	O	O	O
replicated	replicated	O	O	O	O
in	in	O	O	O	O
phase	phase	O	O	O	O
B.	b.	O	O	O	O
In	in	O	O	O	O
phase	phase	O	O	O	O
A	a	O	O	O	O
,	,	O	O	O	O
extrapyramidal	extrapyramidal	O	O	OTHERS	I
signs	signs	O	O	OTHERS	I
tended	tended	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
greater	greater	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
standard	standard	O	O	O	O
dose	dose	O	O	O	O
than	than	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
two	two	O	O	O	O
conditions	conditions	O	O	O	O
,	,	O	O	O	O
primarily	primarily	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
subgroup	subgroup	O	O	O	O
(	(	O	O	O	O
20	20	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
moderate	moderate	O	O	O	O
to	to	O	O	O	O
severe	severe	O	O	O	O
signs	signs	O	O	O	O
.	.	O	O	O	O

Low-dose	low-dose	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
did	did	O	O	O	O
not	not	O	O	O	O
differ	differ	O	O	O	O
from	from	O	O	O	O
placebo	placebo	O	O	O	O
on	on	O	O	O	O
any	any	O	O	O	O
measure	measure	O	O	O	O
of	of	O	O	O	O
efficacy	efficacy	O	O	O	O
or	or	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
results	results	O	O	O	O
indicated	indicated	O	O	O	O
a	a	O	O	O	O
favorable	favorable	O	O	O	O
therapeutic	therapeutic	O	O	O	O
profile	profile	O	O	O	O
for	for	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
2	2	O	O	O	O
-	-	O	O	O	O
3	3	O	O	O	O
mg/day	mg/day	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
a	a	O	O	O	O
subgroup	subgroup	O	O	O	O
developed	developed	O	O	O	O
moderate	moderate	O	O	O	O
to	to	O	O	O	O
severe	severe	O	O	O	O
extrapyramidal	extrapyramidal	O	O	OTHERS	I
signs	signs	O	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
starting	starting	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
1	1	O	O	O	O
mg/day	mg/day	O	O	O	O
with	with	O	O	O	O
gradual	gradual	O	O	O	O
,	,	O	O	O	O
upward	upward	O	O	O	O
dose	dose	O	O	O	O
titration	titration	O	O	O	O
is	is	O	O	O	O
recommended	recommended	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
narrow	narrow	O	O	O	O
therapeutic	therapeutic	O	O	O	O
window	window	O	O	O	O
observed	observed	O	O	O	O
with	with	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
may	may	O	O	O	O
also	also	O	O	O	O
apply	apply	O	O	O	O
to	to	O	O	O	O
other	other	O	O	O	O
neuroleptics	neuroleptics	CHEMICALS	O	OTHERS	I
used	used	O	O	O	O
in	in	O	O	O	O
Alzheimer	alzheimer	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
with	with	O	O	O	O
psychosis	psychosis	O	DISEASE	OTHERS	I
and	and	O	O	O	O
disruptive	disruptive	O	O	OTHERS	I
behaviors	behaviors	O	O	OTHERS	I
.	.	O	O	O	O

